Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
152 Results for "
CYP2C9
" in MedChemExpress (MCE) Product Catalog:
Products (152)
152 Results for "CYP2C9" in MCE Product Catalog:
Target:
Indoleamine 2,3-Dioxygenase (IDO) Calcium Channel Sodium Channel Potassium Channel Cytochrome P450
Research Areas:
IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC50 of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC50s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases .
Cat. No.: HY-B0258S1
CAS No.: 1160569-36-7
Synonyms: CI-719-d6-1
Cat. No.: HY-147807
CAS No.: 2789676-44-2
Target:
Research Areas:
HIV-1 inhibitor-40 (Compound 4ab) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 with an EC50 of 1.9 nM. HIV-1 inhibitor-40 displays weak CYP sensitivity with IC50 values of 5.16 μM and 4.51 μM against CYP2C9 and CYP2C19, respectively. HIV-1 inhibitor-40 has no apparent in vivo acute toxicity .
Cat. No.: HY-169119
Target:
Research Areas:
Antifungal agent 114 (Compound 19g) is an inhibitor for Cytochrome P450, that inhibits CYP1A2, CYP2C9, CYP2C19 CYP2D6 and CYP3A4 at 10 μM. Antifungal agent 114 exhibits antifungal activity against Cryptococcus neoformans, Candida and Aspergillus, with MIC <0.0625 μg/mL. Antifungal agent 114 exhibits good metabolic stability in human liver microsomes with a half-time of 107 minutes .
Cat. No.: HY-17356S1
CAS No.: 1092484-57-5
Cat. No.: HY-17356S2
CAS No.: 1261395-55-4
Cat. No.: HY-131495R
CAS No.: 52079-10-4
Synonyms: (S)-6-Desmethyl Naproxen (Standard)
Target:
Research Areas:
(S)-6-O-Desmethylnaproxen (Standard) is the analytical standard of (S)-6-O-Desmethylnaproxen. This product is intended for research and analytical applications. (S)-6-O-Desmethylnaproxen ((S)-6-Desmethyl Naproxen) is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (+)-naproxen ((S)-naproxen). (S)-6-O-Desmethylnaproxen is formed from (S)-naproxen by the cytochrome P450 (CYP) isoforms CYP1A2 and CYP2C9.
Cat. No.: HY-141547
CAS No.: 1432913-44-4
Target:
Research Areas:
Nav1.7-IN-8 is a potent blockage of NaV1.7 with high selectivity for the inhibition of NaV1.7 over the subtypes hNaV1.1 and hNaV1.5. Nav1.7-IN-8 inhibits CYP2C9 and CYP3A4 with an IC50 of 0.17 μM and 0.077 μM, respectively. Nav1.7-IN-8 displays significant analgesic effects in rodent models of acute and inflammatory pain .
Cat. No.: HY-15565R
CAS No.: 832714-46-2
Target:
Research Areas:
APD668 (Standard) is the analytical standard of APD668. This product is intended for research and analytical applications. APD668 is a potent, selective and orally active agonist of G-protein coupled receptor GPR119, with EC50s of 2.7 nM and 33 nM for hGPR119 and rGPR119, respectively. APD668 shows no significant inhibition of any of the five major CYP isoforms with the exception of CYP2C9 (Ki=0.1 μM). APD668 can be used for the research of steatohepatitis and diabetes .
Cat. No.: HY-159143
Research Areas:
BChE-IN-33 (compound 4r), an arylaminonaphthol derivative, is a potent butyrylcholinesterase (BChE) inhibitor with an IC50 of 14.78 µM. BChE-IN-33 also inhibits CYP2C19, CYP2C9, CYP2D6. BChE-IN-33 shows potent antioxidant activity with IC50 values of 150.48 μM, 2.56 μM and 4.61 μM by DPPH, ABTS, Ferric-phenanthroline assay, respectively. BChE-IN-33 has the potential for Alzheimer research .
Cat. No.: HY-172897
Research Areas:
EGFR/DHFR-IN-2 (9b) is a dual h-DHFR/EGFR TK inhibitor, with IC50 values of 0.192 μM and 0.109 μM for h-DHFR and EGFR, respectively. EGFR/DHFR-IN-2 (9b) halts the cell cycle at the G1/S phase and induces apoptosis. EGFR/DHFR-IN-2 (9b) is a potential inhibitor of CYP2C9 and CYP3A4. EGFR/DHFR-IN-2 (9b) can be used in the cancer research .
Synonyms: 7,8-Dihydrokawain (Standard); 7,8-Dihydrokavain (Standard); Marindinin (Standard)
Category:
Target:
Cat. No.: HY-100386S
CAS No.: 1246817-49-1
Synonyms: PCR 5332-d4
Cat. No.: HY-148597
CAS No.: 2847092-41-3
Target:
Research Areas:
FGFR-IN-10 is an orally active inhibitor of FGFR and Cytochrome P450 (CYPs). FGFR-IN-10 inhibits wide type and V564F mutant FGFR2 with IC50s of 104.1 nM and 43.6 nM, respectively. FGFR-IN-10 also inhibits CYPs with IC50s of 3.33 μM (CYP2C9), 18.75 μM (CYP2C19), 4.34 μM (CYP2CD6), and 0.69 μM (CYP3A4), respectively .
Cat. No.: HY-11103R
CAS No.: 210421-74-2
Synonyms: IPI 1040 sodium (Standard); TBC11251 sodium (Standard)
Research Areas:
Sitaxsentan (sodium) (Standard) is the analytical standard of Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) (HY-11103). This product is intended for research and analytical applications. Sitaxsentan sodium is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan sodium exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
Cat. No.: HY-B0153AS
Cat. No.: HY-184843
CAS No.: 38063-51-3
Target:
Research Areas:
4-Methoxywarfarin (compound 15) is a racemic inhibitor of cytochrome P450 2C9 (CYP2C9). 4-Methoxywarfarin inhibits CYP2C9-catalyzed S-warfarin 7-hydroxylation with a Ki of 11 μM. 4-Methoxywarfarin is applicable to studies related to CYP2C9 inhibition, warfarin metabolism, and the structure-activity relationship of CYP2C9 inhibitors .
Cat. No.: HY-164031A
CAS No.: 525-26-8
Target:
Research Areas:
Cloperidone hydrochloride acts as an inhibitor and substrate of CYP2C9, with an IC50 of 17.7 μM. Cloperidone hydrochloride exhibits enhanced cytotoxicity in cells expressing CYP2C9. It can be used in the research of sedative/hypnotic-related diseases .
Target:
Research Areas:
Pyranocoumarin (Compound 13) is a heterocyclic scaffold (coumarin + pyran ring fusion). Pyranocoumarin inhibits the S-warfarin hydroxylation catalyzed by CYP2C9 .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
